View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
September 21, 2018

Deals and M&As this week: LEO Pharma, Valeo Pharma, Allergan

LEO Pharma and MorphoSys have formed a strategic partnership to develop peptide-derived therapeutics.

LEO Pharma and MorphoSys have formed a strategic partnership to develop peptide-derived therapeutics.

LEO Pharma will select lead molecules using the MorphoSys proprietary peptide technology platform and will be responsible for the development and commercialisation of drugs in the dermatology sector.

MorphoSys will have an exclusive option to secure worldwide rights to drugs developed under the collaboration in the field of oncology. It will also receive milestone payments and other royalties upon commercialisation of the drugs.

Based in Denmark, LEO Pharma is a pharmaceutical company engaged in the manufacture of drugs for dermatologic and thrombotic disorders, while MorphoSys is a German pharmaceutical company engaged in the research and development of therapeutic drugs.

Valeo Pharma and Besins Healthcare have partnered to commercialise Utrogestan® vaginal capsule in Canada.

Approved by Health Canada, Utrogestan® is a progesterone medication indicated for luteal phase support during in-vitro fertilisation cycles.

Based in Canada, Valeo Pharma is a Canada-based provider of therapeutic solutions for healthcare professionals, while Besins Healthcare is a Thailand-based developer of pharmaceutical drugs indicated for the treatment of gynaecological, fertility and obstetrical conditions.

Allergan has agreed to acquire US-based clinical-stage biotechnology company Bonti for $195m.

Bonti will also receive commercial milestone payments from Allergan, as part of the agreement.

Based in Ireland, Allergan is a pharmaceutical research and development company.

The acquisition will expand the acquirer company’s aesthetics product portfolio.

“Allergan has agreed to acquire US-based clinical-stage biotechnology company Bonti for $195m.”

Vifor Pharma Group has increased its interest in ChemoCentryx from 6.6% to 21.2%, through the acquisition of additional 7.3 million common shares from GlaxoSmithKline.

Vifor Pharma has gained exclusive rights to the commercialisation of avacopan and CCX140, which is indicated for the treatment of orphan and rare renal diseases, as per the current in-licensing agreements.

Based in Switzerland, Vifor Pharma is a manufacturer and distributor of pharmaceutical products, while ChemoCentryx is a US-based clinical-stage biopharmaceutical company engaged in the development of medicines for inflammatory and autoimmune diseases.

The transaction will enhance Vifor Pharma’s position in the field of nephrology and enable it to provide new treatments for patients suffering from serious kidney diseases.

Canada-based pharmaceutical company Aralez Pharmaceuticals and its affiliates have signed two separate agreements to sell its assets to Nuvo Pharmaceuticals and Deerfield Management Company.

Alarez will sell the royalties related to VIMOVO® along with its Canadian operations to Nuvo Pharmaceuticals for $110m, as well as another asset, TOPROL-XL®, to Deerfield for $130m.

Based in Canada, Nuvo Pharmaceuticals is a manufacturer and distributor of pharmaceutical products, while Deerfield is a private equity firm based in the US.

Moelis & Company and Alvarez & Marsal have been appointed as the legal advisers to Alarez for the transaction.

Arrow Pharmaceuticals has announced the Australian Competition and Consumer Commission’s clearance for its merger with Apotex Australia.

Both Arrow and Apotex are Australia-based importers and distributors of generic prescription and over-the-counter drugs.

The transaction is subject to closure of definitive agreements and approval from the Australian Foreign Investment Review Board.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU